首页> 外国专利> Monoclonal antibodies specific for mutated E-Cadherin peptide sequences

Monoclonal antibodies specific for mutated E-Cadherin peptide sequences

机译:对突变的E-钙黏着蛋白肽序列具有特异性的单克隆抗体

摘要

A novel monoclonal antibody recognises one or more of the following mutated (through deletion or point mutation) E-cadherin sequences: PGLRRQKRDW/IKSNKDKEGK (563del63); QGADTPPVGV/ERETGWLKVT (706del9); LSQDPELPDK/NRNTGVISVV (1036del15); SVVTTGLDRE/YKGQVPENEA (1103del129); DNPPIFNPTT/GLDFEAKQQY (1232del183); NNDGILKTAK/VSLTTSTATV (1414del69); TAVITVTDTNANPPIFNPTT (Asp370Ala); EVSLTTSTATDTVDVLDVNE (Val473Asp); EVSLTTSTATDTVDVLDVNE (Arg598Gln); AVSSNGNAVEE/ILITVTDQN (826del19). "/" shows the position of a deletion. Also claimed are: (1) a cell line producing the antibody of (1); (2) a therapeutic or diagnostic agent comprising at least one nucleic acid that hybridises under stringent conditions to at least a portion of a DNA sequence encoding one of the above mutated E-cadherin sequences, or the complementary strand or RNA transcript of such a DNA sequence, provided that the portion embraces the mutation, where the DNA sequence is selected from: CCT GGC CTC AGA AGA CAG AAG AGA GAC TGG/ATC AAA TCC AAC AAAGACAAAGAAGGCAAG (563del63); CAA GGA GCT GAC ACA CCC CCT GTT GGT GT/T GAA AGA GAA ACA GGA TGG CTG AAG GTG ACA (706del9); CTC AGC CAA GAT CCT GAG CTC CCT GAC AAA / AAC AGG AAC ACA GGA GTC ATC AGT GTG GTC (1036del15); AGT GTG GTC ACC ACT GGG CTG GAC CGA GAG / TAC AAG GGT CAG GTG CCT GAG AAC GAG GCT (1103del129); GAT AAT CCT CCG ATC TTC AAT CCC ACC ACG / GGC TTG GAT TTT GAG GCC AAG CAG CAG TAC (1232del183); AAC AAC GAT GGC ATT TTG AAA ACA GCA AAG / TCT CTC ACC ACC TCC ACA GCC ACC GTC (1414del69); ACA GCT GTG ATC ACA GTC ACT GAC ACC AAC GCT AAT CCT CCG ATC TTC AAT CCC ACC ACG (Asp370Ala); GAG GTC TCT CTC ACC ACC TCC ACA GCC ACC GAC ACC GTG GAT GTG CTG GAT GTG AAT GAA (Va1473AsP); GTG AAT GAC AAC GCC CCC ATA CCA GAA CCT CAA ACT ATA TTC TTC TGT GAG AGG AAT CCA (Arg598Gln); GCT GTG TCA TCC AAC GGG AAT GCA GTT GAG GA / G ATT TTG ATC ACG GTA ACC GAT CAG AAT (826del9); (3) DNA oligonucleotides encoding the amino acid sequences of (1); and (4) oligopeptides comprising the amino acid sequences of mutated E-cadherin as above.
机译:一种新型单克隆抗体可识别以下一个或多个以下突变的(通过缺失或点突变)E-钙粘蛋白序列:PGLRRQKRDW / IKSNKDKEGK(563del63); QGADTPPVGV / ERETGWLKVT(706del9); LSQDPELPDK / NRNTGVISVV(1036del15); SVVTTGLDRE / YKGQVPENEA(1103del129); DNPPIFNPTT / GLDFEAKQQY(1232del183); NNDGILKTAK / VSLTTSTATV(1414del69); TAVITVTDTNANPPIFNτPTT(Asp370Ala); EVSLTTSTATDTVDVLDVNE(Val473Asp); EVSLTTSTATDTVDVLDVNE(Arg598Gln); AVSSNGNAVEE / ILITVTDQN(826del19)。 “ /”显示删除的位置。还要求保护:(1)产生(1)的抗体的细胞系; (2)一种治疗剂或诊断剂,其包含至少一种在严格条件下与编码上述突变的E-钙粘蛋白序列之一的DNA序列的至少一部分杂交的核酸或该DNA的互补链或RNA转录物。序列,条件是该部分包含突变,其中DNA序列选自:CCT GGC CTC AGA AGA CAG AAG AGA GAC TGG / ATC AAA TCC AAC AAAGACAAAGAAGGCAAG(563del63); CAA GGA GCT GAC ACA CCC CCT GTT GGT GT / T GAA AGA GAA ACA GGA TGG CTG AAG GTG ACA(706del9); CTC AGC CAA GAT CCT GAG CTC CCT GAC AAA / AAC AGG AAC ACA GGA GTC ATC AGT GTG GTC(1036del15); AGT GTG GTC ACC ACT GGG CTG GAC CGA GAG / TAC AAG GGT CAG GTG CCT GAG AAC GAG GCT(1103del129); GAT AAT CCT CCG ATC TTC AAT CCC ACC ACG / GGC TTG GAT TTT GAG GCC AAG CAG CAG TAC(1232del183); AAC AAC GAT GGC ATT TTG AAA ACA GCA AAG / TCT CTC ACC ACC TCC ACA GCC ACC GTC(1414del69); ACA GCT GTG ATC ACA GTC ACT GAC ACC AAC GCT AAT CCT CCG ATC TTC AAT CCC ACC ACG(Asp370Ala); GAG GTC TCT CTC ACC ACC TCC ACA GCC ACC GAC ACC GTG GAT GTG CTG GAT GTG AAT GAA(Va1473AsP); GTG AAT GAC AAC GCC CCC ATA CCA GAA CCT CAA ACT ATA TTC TTC TGT GAG AGG AAT CCA(Arg598Gln); GCT GTG TCA TCC AAC GGG AAT GCA GTT GAG GA / G ATT TTG ATC ACG GTA ACC GAT CAG AAT(826del9); (3)编码(1)的氨基酸序列的DNA寡核苷酸; (4)寡肽,其包含如上所述的突变的E-钙粘着蛋白的氨基酸序列。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号